Actinomadura graeca sp. nov.: A novel producer of the macrocyclic antibiotic zelkovamycin

Synthesis and Anticancer Activity Assessment of Zelkovamycin Analogues

The zelkovamycin family is a class of cyclic octapeptides with potent antibacterial and antiviral activity. Due to their unique chemical structures and excellent bioactivity, zelkovamycins have consistently attracted the interest of synthetic chemists. However, only the total synthesis of zelkovamycin and zelkovamycin G has been reported until now. The current work presents, for the first time, the synthesis of zelkovamycin analogues, along with their anticancer activity assessment. Firstly, the corresponding chain peptide based on the amino acid sequence of zelkovamycin H was synthesized using the Fmoc solid-phase peptide strategy. This was followed by cyclization under high dilution conditions to obtain compound 21, and its structure was elucidated by NMR analysis. The results confirm that compound 21 is not the natural product of zelkovamycin H. We deduced that during the synthesis of peptide 12, the D-Abu residue epimerized to the L-Abu form, leading to the formation of peptide 20, which blocked our efforts during the synthesis of zelkovamycin H. Two more analogues, 22 and 23, were synthesized by changing the structure of amino acid residues using the same strategy. The anticancer activity of analogues 21-23 against Huh-7 cells was evaluated in vitro; however, their IC50 values were >50 μM.

Natural Products That Contain Higher Homologated Amino Acids

This review focuses on discussing natural products (NPs) that contain higher homologated amino acids (homoAAs) in the structure as well as the proposed and characterized biosynthesis of these non-proteinogenic amino acids. Homologation of amino acids includes the insertion of a methylene group into its side chain. It is not a very common modification found in NP biosynthesis as approximately 450 homoAA-containing NPs have been isolated from four bacterial phyla (Cyanobacteria, Actinomycetota, Myxococcota, and Pseudomonadota), two fungal phyla (Ascomycota and Basidiomycota), and one animal phylum (Porifera), except for a few examples. Amino acids that are found to be homologated and incorporated in the NP structures include the following ten amino acids: alanine, arginine, cysteine, isoleucine, glutamic acid, leucine, phenylalanine, proline, serine, and tyrosine, where isoleucine, leucine, phenylalanine, and tyrosine share the comparable enzymatic pathway. Other amino acids have their individual homologation pathway (arginine, proline, and glutamic acid for bacteria), likely utilize the primary metabolic pathway (alanine and glutamic acid for fungi), or have not been reported (cysteine and serine). Despite its possible high potential in the drug discovery field, the biosynthesis of homologated amino acids has a large room to explore for future combinatorial biosynthesis and metabolic engineering purpose.

Isolation, Identification and Screening of Saharan Actinomycete Strain Streptomyces fimbriatus AC31 Endowed with Antimicrobial Activity

The increasing global public health concern of antimicrobial resistance (AMR) necessitates exploration of natural antimicrobial agents as potential alternatives. This study aimed to investigate antimicrobial activities of Saharan actinomycetes, with specific focus on the strain Streptomyces fimbriatus AC31, that holds promising potential as an alternative to combat AMR. In this context, 32 actinomycetes were isolated from El Atteuf (Ghardaïa), Algeria. Isolates obtained were characterized morphologically and biochemically. Screened isolate was identified by 16S rRNA gene sequencing. Classification of actinomycete isolates was carried out by UPGMA (Unweighted Pair Group Method with Arithmetic Mean). Then, they were screened for their antimicrobial activity by cross-streak method. Identification of 32 isolates revealed 5 genera: Streptomyces (65.63%), Nocardia (9.38%), Streptosporangium (9.38%), Nocardiopsis (9.38%) and Actinomadura (6.25%). According to the biochemical and physiological characteristics, UPGMA classified the isolates in 4 phenons. A number of 24 (75.00%) isolates were active against Gram-positive bacteria, 21 (65.63%) isolates were effective against Gram-negative bacteria, and 25 (78.13%) isolates inhibited Candida albicans. Screened strain Streptomyces fimbriatus AC31 showed highest antagonistic activity and revealed an inhibition zones of 41, 38, 41, 42, and 44 mm, against B. subtilis (ATCC 6633), E. coli (ATCC 8739), S. typhimurium (ATCC 13331), S. aureus (ATCC 6538) and C. albicans (ATCC 10231), respectively. Phylogenetic identification of the AC 31 isolate using 16S rRNA gene sequence showed similarity of 100% with Streptomyces fimbriatus NBRC 15411T. Actinomycete isolates characterized in this study were endowed with antimicrobial activity against various pathogenic microorganisms that could be used efficiently in developing new antimicrobial substances.

Zelkovamycins F and G, Cyclopeptides with Cα-Methyl-threonine Residues, from an Endophytic Kitasatospora sp

Zelkovamycins F and G (1 and 2), two new natural cyclic octapeptides possessing the unprecedented nonproteinogenic amino acid residues l-α-methyl-threonine and l-α-methyl-allo-threonine, respectively, along with four new analogues, zelkovamycins H-K (3-6), were identified from the endophytic Kitasatospora sp. CPCC 204717. Their structures were elucidated by detailed analysis of NMR and HRESIMS/MS spectroscopic data. The configurations of amino acid residues were determined by Marfey's analysis combined with NMR calculations. Compounds 1, 2, and 4 showed potent antibacterial activity against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. The structure-activity relationship study revealed that the 2-methyl-3-oxobutyrine and sarcosine residues played important roles in their antibacterial activities. Zelkovamycin (7) and zelkovamycin E (8) exhibited significant antiviral activity against the hepatitis C virus.